首页> 外文期刊>Critical care : >Drotrecogin alfa (activated) in the subgroup of patients with multiple organ dysfunction (MOD) during a global, single-arm, open-label trial in adult patients with severe sepsis (ENHANCE): comparisons with PROWESS
【24h】

Drotrecogin alfa (activated) in the subgroup of patients with multiple organ dysfunction (MOD) during a global, single-arm, open-label trial in adult patients with severe sepsis (ENHANCE): comparisons with PROWESS

机译:在患有严重脓毒症(ENHANCE)的成年患者的整体,单臂,开放标签试验中,多器官功能障碍(MOD)患者亚组中的Drotrecogin alfa(已激活):与PROWESS的比较

获取原文
获取外文期刊封面目录资料

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号